Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Surface antigen inactivated influenza vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1: Fluvirin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Surface antigen inactivated influenza vaccine | BIOLOGICAL | 1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition |
Inclusion Criteria: * Healthy Subjects eligible for enrollment into this study are male and female adult volunteers Exclusion Criteria: * Any serious disease
Surface antigen inactivated influenza vaccine is used for influenza, a viral infection of the respiratory tract. It is an investigational vaccine being developed to provide immunity against seasonal influenza strains. The vaccine is currently in clinical development and has not been approved for public use.
Surface antigen inactivated influenza vaccine is being developed by Novartis AG, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol NVS. The company conducted a Phase 2 clinical trial to evaluate the vaccine's immunogenicity in healthy adults.
Surface antigen inactivated influenza vaccine is in Phase 2 clinical development. It is an investigational vaccine, meaning it has not yet received regulatory approval. The Phase 2 trial, which has been completed, assessed the vaccine's ability to generate an immune response in healthy volunteers.
Surface antigen inactivated influenza vaccine has one completed clinical trial, registered as NCT00518453. This Phase 2 study, titled "Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008," enrolled 129 participants in the United Kingdom. The trial evaluated the vaccine's immunogenicity in healthy adults aged 18 years and older.
Surface antigen inactivated influenza vaccine works by presenting inactivated surface antigens from influenza viruses to the immune system. This exposure triggers an immune response, including the production of antibodies, which can recognize and neutralize the virus upon future exposure. The vaccine is designed to protect against seasonal influenza strains.